RU95105970A - Новые дельта-амино-гамма-гидрокси-омега-арил-амиды алкан-карбоновой кислоты - Google Patents

Новые дельта-амино-гамма-гидрокси-омега-арил-амиды алкан-карбоновой кислоты

Info

Publication number
RU95105970A
RU95105970A RU95105970/04A RU95105970A RU95105970A RU 95105970 A RU95105970 A RU 95105970A RU 95105970/04 A RU95105970/04 A RU 95105970/04A RU 95105970 A RU95105970 A RU 95105970A RU 95105970 A RU95105970 A RU 95105970A
Authority
RU
Russia
Prior art keywords
rmeans
lower alkyl
hydroxy
substituted
cycloalkyl
Prior art date
Application number
RU95105970/04A
Other languages
English (en)
Inventor
Гешке Рихард
Ch]
Клаус Майбаум Юрген
Шиллинг Вальтер
De]
Стутз Стэфан
Ригольер Паскаль
Ямагуши Ясушика
Клод Соген Ниссим
Херольд Петер
Fr]
Original Assignee
Циба - Гейге А.Г. (CH)
Циба - Гейге А.Г.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4204102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU95105970(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Циба - Гейге А.Г. (CH), Циба - Гейге А.Г. filed Critical Циба - Гейге А.Г. (CH)
Publication of RU95105970A publication Critical patent/RU95105970A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/11—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton
    • C07C255/13—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Дельта-амино-гамма- гидрокси-омега- арил-амиды алкан-карбоновой кислоты формулы I, приведенной в описании, и их соли обладают свойствами, сдерживающими активность ренина и могут быть использованы в качестве антигипертенсивных лекарственных биологически активных веществ.

Claims (1)

  1. Дельта-амино-гамма- гидрокси-омега- арил-амиды алкан-карбоновой кислоты формулы I, приведенной в описании, и их соли обладают свойствами, сдерживающими активность ренина и могут быть использованы в качестве антигипертенсивных лекарственных биологически активных веществ.
RU95105970/04A 1994-04-18 1995-04-13 Новые дельта-амино-гамма-гидрокси-омега-арил-амиды алкан-карбоновой кислоты RU95105970A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1169/94-3 1994-04-18
CH116994 1994-04-18

Publications (1)

Publication Number Publication Date
RU95105970A true RU95105970A (ru) 1997-01-10

Family

ID=4204102

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95105970/04A RU95105970A (ru) 1994-04-18 1995-04-13 Новые дельта-амино-гамма-гидрокси-омега-арил-амиды алкан-карбоновой кислоты

Country Status (27)

Country Link
US (5) US5559111A (ru)
EP (1) EP0678503B1 (ru)
JP (1) JP3240322B2 (ru)
KR (1) KR100353779B1 (ru)
CN (2) CN1153759C (ru)
AT (1) ATE183997T1 (ru)
AU (1) AU699616B2 (ru)
BR (1) BR1100656A (ru)
CA (1) CA2147056C (ru)
CY (4) CY2208B1 (ru)
CZ (1) CZ287935B6 (ru)
DE (4) DE59506707D1 (ru)
DK (1) DK0678503T3 (ru)
ES (1) ES2137478T3 (ru)
FI (1) FI118336B (ru)
GR (1) GR3031997T3 (ru)
HK (1) HK1070881A1 (ru)
HU (2) HUT71701A (ru)
IL (1) IL113403A (ru)
LU (2) LU91373I2 (ru)
MY (1) MY119161A (ru)
NL (2) NL300296I2 (ru)
NO (4) NO310410B1 (ru)
NZ (1) NZ270936A (ru)
RU (1) RU95105970A (ru)
TW (2) TW366341B (ru)
ZA (3) ZA953052B (ru)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4408534A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Substituierte N-Ethyl-Glycinderivate zur Herstellung von PNA und PNA-/DNA-Hybriden
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0716077A1 (de) * 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
US6465650B1 (en) 1995-03-13 2002-10-15 Aventis Pharma Deutschland Gmbh Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids
CN1210268C (zh) * 1997-12-16 2005-07-13 沃尼尔·朗伯公司 ((环)烷基取代的)－γ－氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) * 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6423850B1 (en) 1999-06-18 2002-07-23 E.I. Du Pont De Nemours And Company Preparation and use of gamma-butyrolactones as cross-linking agents
US6833460B2 (en) * 1999-06-18 2004-12-21 E. I. Du Pont De Nemours And Company Preparation and use of gamma-butyrolactones as cross-linking agents
WO2001009079A1 (de) * 1999-07-29 2001-02-08 Speedel Pharma Ag 2-alkyl-5-halogen-pent-4-encarbonsäuren und deren herstellung
BR0112128A (pt) * 2000-07-03 2003-05-13 Speedel Pharma Ag Processo para a preparação de (r)-2-alquil-3-fenil-1-propanóis
WO2002002508A1 (en) 2000-07-05 2002-01-10 Speedel Pharma Ag Process for the preparation of substituted octanoyl amides
ATE267800T1 (de) * 2000-07-25 2004-06-15 Speedel Pharma Ag Verfahren zur herstellung von substituierten octanoyl-amiden
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DE60123911T2 (de) * 2000-12-14 2007-05-31 Speedel Pharma Ag Verfahren zur Herstellung von Aryloctanoyl-amiden
JP3440082B2 (ja) 2001-02-19 2003-08-25 科学技術振興事業団 電気自動車用インホイールモーター
US7153675B2 (en) 2001-05-15 2006-12-26 Speedel Pharma Ag Process for the preparation of substituted carboxylic esters
MXPA03011502A (es) * 2001-06-11 2004-03-26 Upjohn Co Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.
BR0213357A (pt) * 2001-10-18 2004-10-26 Novartis Ag Compostos orgânicos
US20050101638A1 (en) * 2002-11-08 2005-05-12 Webb Randy L. Combination of organic compounds
ES2369216T3 (es) * 2002-05-17 2011-11-28 Novartis Pharma Ag Composición farmacéutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diurético.
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
US20060089355A1 (en) * 2002-06-11 2006-04-27 Michel Maillard Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides
WO2003103653A1 (en) * 2002-06-11 2003-12-18 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
BR0313743A (pt) * 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
US7049469B2 (en) 2002-10-24 2006-05-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing (R)-salbutamol
US7351738B2 (en) 2002-11-27 2008-04-01 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
EP1660488A1 (en) * 2003-08-25 2006-05-31 Warner-Lambert Company LLC Novel antimicrobial aryloxazolidinone compounds
BRPI0417017A (pt) 2003-11-26 2007-02-21 Novartis Ag compostos orgánicos
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
PE20050596A1 (es) * 2003-12-19 2005-10-18 Novartis Ag Microemulsion que comprende un inhibidor renina
WO2005070406A1 (en) * 2004-01-22 2005-08-04 Novartis Ag Combination of organic compounds
TW200535131A (en) * 2004-01-23 2005-11-01 Speedel Experimenta Ag Organic compounds
DE602005025344D1 (de) * 2004-01-23 2011-01-27 Novartis Ag Aminoalkoholderivate und deren wirkung als renininhibitoren
BRPI0508880A (pt) 2004-03-17 2007-09-04 Novartis Ag uso de compostos orgánicos
US20070191487A1 (en) * 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
PE20142101A1 (es) * 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
EP1725530A1 (en) * 2004-03-19 2006-11-29 Speedel Experimenta AG Organic compounds
DE602005012481D1 (de) * 2004-03-19 2009-03-12 Speedel Experimenta Ag 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
WO2005095876A1 (en) 2004-04-01 2005-10-13 Cucumber Limited Delivery and storage of goods
GB0419361D0 (en) 2004-08-31 2004-10-06 Novartis Ag Organic compounds
PL1799199T3 (pl) 2004-10-08 2012-09-28 Novartis Ag Zastosowanie inhibitorów reniny do zapobiegania lub leczenia dysfunkcji rozkurczowej albo rozkurczowej niewydolności serca
TW200631929A (en) * 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
TW200633983A (en) * 2004-12-10 2006-10-01 Speedel Experimenta Ag 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-nonanamides
WO2006083924A1 (en) * 2005-02-02 2006-08-10 Vitae Pharmaceuticals, Inc. 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
EP1856032A1 (en) * 2005-03-11 2007-11-21 Speedel Experimenta AG Heterocyclic-substituted alkanamides useful as renin inhibitors
CN101171230A (zh) * 2005-03-11 2008-04-30 斯皮德尔实验股份公司 用作肾素抑制剂的杂环取代的链烷酰胺
ES2337826T3 (es) * 2005-03-17 2010-04-29 Basf Se Metodo para la produccion de derivados opticamente activos de acido 3-fenilpropionico y productos de reaccion del mismo.
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
PL1904469T3 (pl) * 2005-07-11 2012-02-29 Novartis Ag Nowe pochodne pirokatechiny
EP1745778A3 (en) 2005-07-20 2007-03-07 Speedel Experimenta AG Diaminoalcohols as therapeutic compounds
EP1910272A4 (en) 2005-07-22 2010-08-04 Merck Frosst Canada Ltd INHIBITORS OF THE RENINE
US8058307B2 (en) * 2005-09-17 2011-11-15 Novartis Ag Alcanoic acid amides substituted by saturated O-heterocycles
EP1764098A1 (en) * 2005-09-17 2007-03-21 Speedel Experimenta AG Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV
AR056197A1 (es) 2005-09-17 2007-09-26 Speedel Experimenta Ag Derivados de 7-metilimidazol[1,2-a]piridin-6-il-8-metil-nonamidas como inhibidores de la renina, composciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de la hipertension arterial
GB0519764D0 (en) 2005-09-28 2005-11-09 Novartis Ag Organic compounds
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
JP2009514809A (ja) * 2005-10-18 2009-04-09 ニコックス エス エイ レニン阻害剤のニトロ誘導体
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
GB2431645A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431648A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431649A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431646A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431642A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
DE102005052195A1 (de) * 2005-10-28 2007-05-03 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von chiralen Octensäurederivaten
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
GB0605688D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
WO2007123718A1 (en) * 2006-03-31 2007-11-01 Vitae Pharmaceuticals, Inc. 1-HETEROCYCLYLAMINO-2-HYDROXY-3-AMINO-ω-ARYLALKANES
US8084485B2 (en) * 2006-03-31 2011-12-27 Vitae Pharmaceuticals, Inc. 6-(aminoalkyl)indazoles
MX2008012729A (es) * 2006-04-03 2008-10-14 Novartis Ag Inhibidores de renina para el tratamiento de hipertension.
CA2656079C (en) 2006-06-23 2012-08-28 Daiichi Sankyo Company, Limited Cyclic amine compound
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
TW200815324A (en) * 2006-06-23 2008-04-01 Daiichi Sankyo Co Ltd Straight chain amine compound
CA2657258A1 (en) 2006-07-20 2008-01-24 Novartis Ag Amino-piperidine derivatives as cetp inhibitors
EP1911762A1 (en) 2006-10-04 2008-04-16 Speedel Experimenta AG Amino alcohols and their use as renin inhibitors
JP2010508370A (ja) * 2006-11-07 2010-03-18 ノバルティス アーゲー ヘミフマル酸アリスキレンの結晶形
US20100130616A1 (en) * 2006-11-09 2010-05-27 Novartis Ag Salt of aliskiren with orotic acid
EP1938812A1 (en) * 2006-12-22 2008-07-02 Speedel Pharma AG Pharmaceutical composition using aliskiren and avosentan
EP1958666A1 (en) 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
AR065792A1 (es) * 2007-03-21 2009-07-01 Speedel Experimenta Ag Proceso para preparar (r o s) -5- (1 -azido-3-(6-metoxi-5-(3-metoxi-propoxi) -piridin-3-ilmetil) -4-metil- pentil) -3-alquil-dihidro-furan-2-ona
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
KR20100016137A (ko) * 2007-04-03 2010-02-12 노파르티스 아게 신규한 방법
US8088954B2 (en) 2007-07-11 2012-01-03 Dsm Ip Assets B.V. Preparation of a saturated aldehyde
US20090076062A1 (en) * 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
US20090082458A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched aliskiren
WO2009040373A2 (en) 2007-09-28 2009-04-02 Novartis Ag Galenical formulations of aliskiren
DE102007049039A1 (de) 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
PE20090982A1 (es) 2007-11-05 2009-08-13 Novartis Ag Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
JP2011503185A (ja) 2007-11-13 2011-01-27 テバ ファーマシューティカル インダストリーズ リミティド ヘミフマル酸アリスキレンの多形形態及びその調製プロセス
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
US8759365B2 (en) 2007-12-03 2014-06-24 Novartis Ag Organic compounds
EP2075244A1 (en) 2007-12-24 2009-07-01 DSMIP Assets B.V. New route to building block for making renin inhibitors
CN102014881A (zh) 2008-02-22 2011-04-13 韩兀生物制药株式会社 药物制剂
EP2275093A2 (en) 2008-04-10 2011-01-19 HanAll Biopharma Co., Ltd. Pharmaceutical formulation
TW201008902A (en) * 2008-05-23 2010-03-01 Teva Pharma Aliskiren monofumarate and processes for preparation thereof
CN102143939A (zh) * 2008-06-06 2011-08-03 特瓦制药工业有限公司 阿利吉仑游离碱的固体形式
EP2143425A1 (de) 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
EP2163245A1 (en) 2008-09-10 2010-03-17 Novartis Ag Renin inhibitors for the treatment of psoriasis
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
RU2535090C2 (ru) 2009-01-28 2014-12-10 Новартис Аг Галеновы препараты органических соединений
EA201190091A1 (ru) 2009-02-05 2012-01-30 Крка, Товарна Здравил, Д. Д., Ново Место Активируемый влагой способ грануляции
WO2010091277A2 (en) 2009-02-05 2010-08-12 Teva Pharmaceutical Industries Ltd. Solid state forms of aliskiren compounds
CN102348452A (zh) 2009-03-20 2012-02-08 诺瓦提斯公司 缬沙坦和阿利吉仑的固定剂量组合的盖仑制剂
US20120003308A1 (en) 2009-03-20 2012-01-05 Sonali Bose Pharmaceutical Composition Comprising Aliskiren
AU2010230260A1 (en) 2009-04-01 2011-11-10 Lek Pharmaceuticals D.D. A process for dimethylation of active methylene groups
RU2550691C2 (ru) * 2009-08-11 2015-05-10 Новартис Аг Раскрытие циклов лактонов и лактамов
WO2011028919A2 (en) 2009-09-03 2011-03-10 Teva Pharmaceutical Industries Ltd. Solid forms of aliskiren hemifumarate and processes for preparation thereof
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
WO2011048523A1 (en) * 2009-10-21 2011-04-28 CarboDesign LLC Process for the manufacture of enantiomerically pure aryloctanoic acids as aliskiren
WO2011051853A1 (en) * 2009-10-29 2011-05-05 CarboDesign LLC Manufacturing process for preparing enaniomerically pure 8- aryloctanoic acid derivatives such as aliskiren
JP2013510145A (ja) * 2009-11-09 2013-03-21 メディヴィル・アクチエボラーグ １，３−オキサゾリジン化合物およびレニン阻害剤としてのそれらの使用方法
US20110113995A1 (en) * 2009-11-13 2011-05-19 Lindsay Corporation Method and apparatus for planting and irrigation
US20110137047A1 (en) * 2009-12-07 2011-06-09 CarboDesign LLC Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
CN101774986B (zh) 2010-01-06 2012-03-28 浙江天宇药业股份有限公司 一种制备阿利克伦及其中间体的方法
CN102140068B (zh) * 2010-01-30 2015-03-11 浙江华海药业股份有限公司 阿利吉仑中间体3-氨基-2,2-二甲基丙酰胺的制备方法
WO2011098258A1 (en) * 2010-02-10 2011-08-18 Ratiopharm Gmbh Salts of aliskiren
WO2011116115A1 (en) 2010-03-16 2011-09-22 Novartis Ag Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing
TR201002256A1 (tr) 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
EP2382967A1 (de) 2010-04-21 2011-11-02 ratiopharm GmbH Aliskiren in Form einer festen Dispersion
EP2382969A1 (en) 2010-04-30 2011-11-02 Sanovel Ilac Sanayi ve Ticaret A.S. Multicoated Aliskiren formulations
CN102241650B (zh) * 2010-05-14 2014-05-07 浙江九洲药业股份有限公司 用于制备阿立克仑的中间体化合物及相关制备方法
IT1400961B1 (it) * 2010-06-04 2013-07-05 Chemo Iberica Sa Processo per la produzione di aliskiren
TW201202178A (en) 2010-06-04 2012-01-16 Chemo Iberica Sa Process for producing Aliskiren
IT1402925B1 (it) * 2010-12-10 2013-09-27 Chemo Iberica Sa Processo per la produzione di aliskiren
CN101913998A (zh) * 2010-07-06 2010-12-15 上海朴颐化学科技有限公司 4-溴-2-(3-甲氧基丙氧基)-苯甲醚的制备方法
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
PT2630118E (pt) 2010-10-19 2015-02-10 Mylan Lab Ltd Síntese do aliskiren
CN102001920B (zh) 2010-11-09 2013-05-15 常州制药厂有限公司 一种药物中间体的制备方法
CN102161627A (zh) * 2011-02-24 2011-08-24 中国药科大学 ω-(N取代-氨基烷基)辛酰胺
EP2551260A1 (en) 2011-07-28 2013-01-30 Chemo Ibérica, S.A. Chemical process for opening ring compounds
CN102942477B (zh) * 2011-08-14 2015-12-02 浙江华海药业股份有限公司 辛烯酸衍生物及其制备方法
CN102351734B (zh) * 2011-09-05 2014-02-26 浙江普洛医药科技有限公司 一种阿利克仑的制备方法
WO2013045505A1 (en) 2011-09-28 2013-04-04 Novartis Ag Biomarkers for raas combination therapy
US8703976B2 (en) * 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
WO2013061224A1 (en) 2011-10-25 2013-05-02 Jubilant Life Sciences Limited Process for the preparation of aliskiren
WO2013118138A1 (en) 2011-12-13 2013-08-15 Laboratories Ltd Mylan Novel process for the preparation of renin inhibitors
CN103172533B (zh) * 2011-12-20 2016-05-04 博瑞生物医药（苏州）股份有限公司 一种阿利克仑半富马酸盐的新晶型及其制备方法和用途
CN103204834A (zh) * 2012-01-11 2013-07-17 南京欧信医药技术有限公司 阿利克伦中间体及其制备方法和应用
US9090537B2 (en) 2012-02-17 2015-07-28 Mylan Laboratories Limited Process for the preparation of aliskiren
WO2013124868A2 (en) 2012-02-21 2013-08-29 Mylan Laboratories Limited Solid form of aliskiren intermediate
ITMI20120354A1 (it) * 2012-03-07 2013-09-08 Friulchem Spa Processo per la produzione di aliskirene
WO2013144979A1 (en) 2012-03-28 2013-10-03 Maylan Laboratories Ltd Process for the preparation of aliskiren
WO2013167715A1 (en) 2012-05-11 2013-11-14 Novartis Ag Dispensing device
WO2013171767A1 (en) 2012-05-18 2013-11-21 Mylan Laboratories Limited An improved process for the preparation of aliskiren
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
JP6521463B2 (ja) * 2013-06-27 2019-05-29 ディーピーエックス ホールディングス ビー．ブイ． 流動層を用いるグリニャール試薬の調製
EP3807898A1 (en) 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
CN112679448B (zh) * 2020-12-31 2022-08-19 苏州昊帆生物股份有限公司 N-(2-氨基乙基)吗啉的制备方法
CN115340472B (zh) * 2022-09-19 2024-05-07 合肥工业大学 一种谷氨酸衍生物及其合成方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337207A (en) * 1980-09-04 1982-06-29 Regents Of The University Of California Biologically active catecholamine derivatives
US4729985A (en) * 1985-08-09 1988-03-08 Pfizer Inc. Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
JPH02124884A (ja) * 1988-07-08 1990-05-14 Zhongguo Yixuekexueyuan Yaowo Yanjiusuo Ｎ―置換アミド誘導体
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities

Also Published As

Publication number Publication date
US5654445A (en) 1997-08-05
TW402582B (en) 2000-08-21
CY2007027I2 (el) 2009-11-04
HU9501076D0 (en) 1995-06-28
EP0678503A1 (de) 1995-10-25
HUT74074A (en) 1996-10-28
NL300386I1 (nl) 2009-07-01
DE122011100052I1 (de) 2012-01-19
US5646143A (en) 1997-07-08
FI118336B (fi) 2007-10-15
FI951771A0 (fi) 1995-04-12
CY2011015I1 (el) 2014-04-09
NZ270936A (en) 1997-06-24
CN1266118C (zh) 2006-07-26
NL300296I1 (nl) 2007-12-03
NO2009011I1 (no) 2009-06-02
CY2009006I2 (el) 2010-07-28
CN1153759C (zh) 2004-06-16
HK1070881A1 (en) 2005-06-30
IL113403A0 (en) 1995-07-31
NL300296I2 (nl) 2008-02-01
CZ287935B6 (cs) 2001-03-14
NO951441D0 (no) 1995-04-12
ZA953052B (en) 1995-10-18
US5705658A (en) 1998-01-06
DE122009000020I1 (de) 2009-08-06
CA2147056A1 (en) 1995-10-19
TW366341B (en) 1999-08-11
JP3240322B2 (ja) 2001-12-17
ZA953050B (en) 1995-11-08
HUT71701A (en) 1996-01-29
FI951771A (fi) 1995-10-19
ES2137478T3 (es) 1999-12-16
KR950032037A (ko) 1995-12-20
ATE183997T1 (de) 1999-09-15
CZ97695A3 (en) 1995-11-15
MY119161A (en) 2005-04-30
LU91564I2 (fr) 2009-07-06
CY2011015I2 (el) 2014-04-09
CA2147056C (en) 2005-10-25
CY2009006I1 (el) 2010-07-28
IL113403A (en) 2001-07-24
US5559111A (en) 1996-09-24
NO310410B1 (no) 2001-07-02
CN1117960A (zh) 1996-03-06
DK0678503T3 (da) 2000-03-20
JPH0881430A (ja) 1996-03-26
NO2007011I1 (no) 2007-12-11
DE122007000071I1 (de) 2008-01-31
NO2009011I2 (no) 2010-11-22
HU9501078D0 (en) 1995-06-28
DE59506707D1 (de) 1999-10-07
LU91373I2 (fr) 2007-12-31
HU226860B1 (en) 2009-12-28
AU699616B2 (en) 1998-12-10
DE122007000071I2 (de) 2009-01-02
NO2011020I1 (no) 2011-09-26
EP0678503B1 (de) 1999-09-01
CY2007027I1 (el) 2009-11-04
AU1642195A (en) 1995-10-26
NO2007011I2 (ru) 2011-07-25
US5627182A (en) 1997-05-06
GR3031997T3 (en) 2000-03-31
NO951441L (no) 1995-10-19
CY2208B1 (en) 2002-11-08
ZA953051B (en) 1995-10-18
KR100353779B1 (ko) 2003-01-08
BR1100656A (pt) 2000-06-06
CN1550491A (zh) 2004-12-01

Similar Documents

Publication Publication Date Title
RU95105970A (ru) Новые дельта-амино-гамма-гидрокси-омега-арил-амиды алкан-карбоновой кислоты
NL300396I1 (nl) Nieuwe derivaten met naftalinestructuren, werkwijze voor de bereiding ervan en de farmaceutische preparaten die deze bevatten
ATE36149T1 (de) Antikonvulsive sulfamatderivate.
ATE176664T1 (de) 2-propylvaleriansäure und 2-propylvalerian- säureamid-derivate und deren verwendung als antikonvulsive mittel
RU94019984A (ru) ПИРИДАЗИНЫ КАК ИНГИБИТОРЫ ИНТЕРЛЕЙКИН-1 β ПРЕОБРАЗУЮЩЕГО ФЕРМЕНТА, ФАРМКОМПОЗИЦИЯ НА ИХ ОСНОВЕ И ИХ ПРИМЕНЕНИЕ
PL328693A1 (en) Novel derivatives of hydroxamic acid useful in treatment of diseases associated with decay of connective tissue
ES8308311A1 (es) Procedimiento para la preparacion de derivados de benzazepina.
NO953332D0 (no) Nye forbindelser
KR950700292A (ko) 니트로소화방법(Nitrosation process)
ATE122042T1 (de) Pyrazoloisoquinoline-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
ATE202704T1 (de) Verwendung eines natrium- oder lysiniumsalzes von crotonsäureamidderivaten zur herstellung eines arzneimittels zur behandlung von krebserkrankungen
DE69624582D1 (de) Ester und amide als pla2-inhibitoren
FR2707089B1 (fr) Nouveaux dérivés d'acide phosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
UY25807A1 (es) Caprolactamas sustituidas, composiciones farmacéuticas que las contienen, y su uso en el tratamiento de tumores.
DE69233255D1 (de) Carbamatanalogen von thiaphysovenin, pharmazeutische zusammensetzungen und verfahren zur hemmung von cholinesterasen
DE59810182D1 (de) Verwendung von quaternären carbonsäurealkanolaminestersalzen als mikrobizide wirkstoffe
BR9606429A (pt) Composto composição e processo para tratamento de disfunção mediada por uPar- ou uPa-
HU910784D0 (en) Process for producing new urea derivatives as well as pharmaceutical preparatives containing these compounds as active substance
EA199700287A1 (ru) Бензамиды для лечения нейродегенеративных заболеваний
ATE169635T1 (de) Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen
RU94033115A (ru) Способ гидрирования
DE69406451D1 (de) Verfahren zur herstellung von n-carbonylarylimine als zwischenprodukte in der synthese von therapeutisch aktiven taxol-derivaten
DE69615200D1 (de) Asymetrische synthese von r und s warfarin und deren ähnlichen verbindungen
ATE248158T1 (de) Synthese von optisch reinen verbindungen als garft-inhibitoren und deren zwischenprodukte
BG51040A3 (bg) Метод за получаване на производни на нафталина